Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor
Amy S. Clark, Thomas B. Karasic, Angela DeMichele, et al.
JAMA Oncology (2015) Vol. 2, Iss. 2, pp. 253-253
Closed Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

Gastric adenocarcinoma
Jaffer A. Ajani, Jeeyun Lee, Takeshi Sano, et al.
Nature Reviews Disease Primers (2017) Vol. 3, Iss. 1
Closed Access | Times Cited: 474
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Kamal Pandey, Hee Jung An, Seung-Ki Kim, et al.
International Journal of Cancer (2018) Vol. 145, Iss. 5, pp. 1179-1188
Open Access | Times Cited: 291
Cell cycle regulation and anticancer drug discovery
Jing‐Wen Bai, Li Yao-Chen, Zhang Guo-jun
Cancer Biology and Medicine (2017) Vol. 14, Iss. 4, pp. 348-348
Open Access | Times Cited: 249
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Smruthi Vijayaraghavan, Cansu Karakaş, Iman Doostan, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 246
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Yibo Xue, Brian Meehan, Zheng Qing Fu, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 158
Cellular Senescence and Ageing: Mechanisms and Interventions
Andreas Mylonas, Ana O’Loghlen
Frontiers in Aging (2022) Vol. 3
Open Access | Times Cited: 77
MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma
Jiaqi Liang, Guoshu Bi, Yiwei Huang, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101057-101057
Closed Access | Times Cited: 24
Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
Mariam Abotaleb, Peter Kubatka, Martin Čaprnda, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 101, pp. 458-477
Closed Access | Times Cited: 159
The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Qi Du, Xiang Guo, Miao Wang, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 123
Pathology, imaging, and treatment of cardiac tumours
Joseph J. Maleszewski, Nandan S. Anavekar, Timothy J. Moynihan, et al.
Nature Reviews Cardiology (2017) Vol. 14, Iss. 9, pp. 536-549
Closed Access | Times Cited: 114
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Nicole M. Kettner, Smruthi Vijayaraghavan, Merih Güray Durak, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 13, pp. 3996-4013
Open Access | Times Cited: 104
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
Yibo Xue, Brian Meehan, Elizabeth Macdonald, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 97
Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non–Small Cell Lung Cancer In Vitro and In Vivo
Sarwat Naz, Anastasia L. Sowers, Rajani Choudhuri, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 16, pp. 3994-4005
Open Access | Times Cited: 91
From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review
Guillermo Valdivia, Ángela Alonso‐Diez, María Dolores Pérez Alenza, et al.
Frontiers in Veterinary Science (2021) Vol. 8
Open Access | Times Cited: 88
MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation
Jian Ma, Lei Li, Bohan Ma, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
Elena De Mattia, Erika Cecchin, Michela Guardascione, et al.
World Journal of Gastroenterology (2019) Vol. 25, Iss. 29, pp. 3870-3896
Open Access | Times Cited: 75
YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer
Fan Li, Yan Xu, Bovey Liu, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 7, pp. 2264-2277
Open Access | Times Cited: 64
Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene Ahn, Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.
JCO Precision Oncology (2020), Iss. 4, pp. 757-766
Open Access | Times Cited: 59
A review of partial nitrification in biological nitrogen removal processes: from development to application
Jipeng Wang, Liangzhong Li, Yongdi Liu, et al.
Biodegradation (2021) Vol. 32, Iss. 3, pp. 229-249
Closed Access | Times Cited: 50
Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Ye Hu, Jiyue Gao, Meiling Wang, et al.
Cancer Management and Research (2021) Vol. Volume 13, pp. 5223-5237
Open Access | Times Cited: 45
An update of new small-molecule anticancer drugs approved from 2015 to 2020
Xiaoxia Liang, Pan Wu, Qian Yang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113473-113473
Closed Access | Times Cited: 41
Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies
Joseph A. Caruso, MyLinh Duong, Jason P.W. Carey, et al.
Cancer Research (2018) Vol. 78, Iss. 19, pp. 5481-5491
Open Access | Times Cited: 50
CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Carolina Rubio, Mónica Martínez‐Fernández, Cristina Segovia, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 1, pp. 390-402
Open Access | Times Cited: 49
Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications
Mohd Yousuf, Manzar Alam, Anas Shamsi, et al.
International Journal of Biological Macromolecules (2022) Vol. 218, pp. 394-408
Closed Access | Times Cited: 25
CDK4/6 inhibitors in HER2-positive breast cancer
Silvia Paola Corona, Andrea Ravelli, Daniele Cretella, et al.
Critical Reviews in Oncology/Hematology (2017) Vol. 112, pp. 208-214
Closed Access | Times Cited: 48
Page 1 - Next Page

Scroll to top